APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cardiovascular Drug Therapy

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Cardiovascular Drug Therapy Industry Growth and Trends Forecast to 2032

22 December 2025124 pages

Choose your research edition.

Industry ResearchCardiovascular Drug Therapy Industry Research Report 2026141 pages · $2,950 USDIndustry Growth & TrendsGlobal Cardiovascular Drug Therapy Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Cardiovascular Drug Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cardiovascular Drug Therapy Market Outlook and Growth Opportunities 2026216 pages · $4,250 USDMarket Analysis & ForecastGlobal Cardiovascular Drug Therapy Market Analysis and Forecast 2026-2032216 pages · $4,950 USD

Market perspective

According to APO Research, the global Cardiovascular Drug Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Cardiovascular Drug Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Cardiovascular Drug Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cardiovascular Drug Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Cardiovascular Drug Therapy market include Zhejiang Huahai Pharmaceutical, Takeda, Sanofi, Johnson & Johnson, Qilu pharmaceutical, Novartis, Merck, Eli Lilly and Gilead, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Cardiovascular Drug Therapy market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Cardiovascular Drug Therapy market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Cardiovascular Drug Therapy market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Cardiovascular Drug Therapy.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Cardiovascular Drug Therapy market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Cardiovascular Drug Therapy Market by Company

Zhejiang Huahai Pharmaceutical

Takeda

Sanofi

Johnson & Johnson

Qilu pharmaceutical

Novartis

Merck

Eli Lilly

Gilead

Pfizer

Daiichi Sankyo

Bayer

Bristol-Myers

Amgen

AstraZeneca

United Therapeutics

Tasly Holding Group

Lepu Medical

CSPC Pharmaceutical

CHIA TAI TIANQING

Boehringer Ingelheim

Cardiovascular Drug Therapy Segment by Type

Oral Medication

Injection

Cardiovascular Drug Therapy Segment by Application

Hospital

Retail

Cardiovascular Drug Therapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cardiovascular Drug Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cardiovascular Drug Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cardiovascular Drug Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Cardiovascular Drug Therapy companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Cardiovascular Drug Therapy Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Cardiovascular Drug Therapy Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Cardiovascular Drug Therapy Market Share by Region (2021-2026) Table 4. Global Cardiovascular Drug Therapy Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Cardiovascular Drug Therapy Market Share by Region (2027-2032) Table 6. Global Cardiovascular Drug Therapy Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Cardiovascular Drug Therapy Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Cardiovascular Drug Therapy Market Size Share by Type (2021-2026) Table 9. Global Cardiovascular Drug Therapy Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Cardiovascular Drug Therapy Market Size Share Forecasted by Type (2027-2032) Table 11. North America Cardiovascular Drug Therapy Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Cardiovascular Drug Therapy Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Cardiovascular Drug Therapy Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Cardiovascular Drug Therapy Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Cardiovascular Drug Therapy Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Cardiovascular Drug Therapy Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Cardiovascular Drug Therapy Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Cardiovascular Drug Therapy Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Cardiovascular Drug Therapy Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Cardiovascular Drug Therapy Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Cardiovascular Drug Therapy Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Cardiovascular Drug Therapy Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Cardiovascular Drug Therapy Market Size Share by Application (2021-2026) Table 24. Global Cardiovascular Drug Therapy Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Cardiovascular Drug Therapy Market Size Share Forecasted by Application (2027-2032) Table 26. North America Cardiovascular Drug Therapy Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Cardiovascular Drug Therapy Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Cardiovascular Drug Therapy Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Cardiovascular Drug Therapy Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Cardiovascular Drug Therapy Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Cardiovascular Drug Therapy Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Cardiovascular Drug Therapy Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Cardiovascular Drug Therapy Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Cardiovascular Drug Therapy Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Cardiovascular Drug Therapy Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Cardiovascular Drug Therapy Industry Trends Table 37. Cardiovascular Drug Therapy Industry Drivers Table 38. Cardiovascular Drug Therapy Industry Opportunities and Challenges Table 39. Cardiovascular Drug Therapy Industry Restraints Table 40. Global Cardiovascular Drug Therapy Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Cardiovascular Drug Therapy Revenue Market Share by Company (2021-2026) Table 42. Global Cardiovascular Drug Therapy Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Cardiovascular Drug Therapy Key Company Headquarters & Area Served Table 44. Global Cardiovascular Drug Therapy Company, Product Type & Application Table 45. Global Cardiovascular Drug Therapy Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Cardiovascular Drug Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Zhejiang Huahai Pharmaceutical Company Information Table 49. Zhejiang Huahai Pharmaceutical Business Overview Table 50. Zhejiang Huahai Pharmaceutical Cardiovascular Drug Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Zhejiang Huahai Pharmaceutical Cardiovascular Drug Therapy Product Portfolio Table 52. Zhejiang Huahai Pharmaceutical Recent Development Table 53. Takeda Company Information Table 54. Takeda Business Overview Table 55. Takeda Cardiovascular Drug Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Takeda Cardiovascular Drug Therapy Product Portfolio Table 57. Takeda Recent Development Table 58. Sanofi Company Information Table 59. Sanofi Business Overview Table 60. Sanofi Cardiovascular Drug Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Sanofi Cardiovascular Drug Therapy Product Portfolio Table 62. Sanofi Recent Development Table 63. Johnson & Johnson Company Information Table 64. Johnson & Johnson Business Overview Table 65. Johnson & Johnson Cardiovascular Drug Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Johnson & Johnson Cardiovascular Drug Therapy Product Portfolio Table 67. Johnson & Johnson Recent Development Table 68. Qilu pharmaceutical Company Information Table 69. Qilu pharmaceutical Business Overview Table 70. Qilu pharmaceutical Cardiovascular Drug Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Qilu pharmaceutical Cardiovascular Drug Therapy Product Portfolio Table 72. Qilu pharmaceutical Recent Development Table 73. Novartis Company Information Table 74. Novartis Business Overview Table 75. Novartis Cardiovascular Drug Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Novartis Cardiovascular Drug Therapy Product Portfolio Table 77. Novartis Recent Development Table 78. Merck Company Information Table 79. Merck Business Overview Table 80. Merck Cardiovascular Drug Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Merck Cardiovascular Drug Therapy Product Portfolio Table 82. Merck Recent Development Table 83. Eli Lilly Company Information Table 84. Eli Lilly Business Overview Table 85. Eli Lilly Cardiovascular Drug Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Eli Lilly Cardiovascular Drug Therapy Product Portfolio Table 87. Eli Lilly Recent Development Table 88. Gilead Company Information Table 89. Gilead Business Overview Table 90. Gilead Cardiovascular Drug Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Gilead Cardiovascular Drug Therapy Product Portfolio Table 92. Gilead Recent Development Table 93. Pfizer Company Information Table 94. Pfizer Business Overview Table 95. Pfizer Cardiovascular Drug Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Pfizer Cardiovascular Drug Therapy Product Portfolio Table 97. Pfizer Recent Development Table 98. Daiichi Sankyo Company Information Table 99. Daiichi Sankyo Business Overview Table 100. Daiichi Sankyo Cardiovascular Drug Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Daiichi Sankyo Cardiovascular Drug Therapy Product Portfolio Table 102. Daiichi Sankyo Recent Development Table 103. Bayer Company Information Table 104. Bayer Business Overview Table 105. Bayer Cardiovascular Drug Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Bayer Cardiovascular Drug Therapy Product Portfolio Table 107. Bayer Recent Development Table 108. Bristol-Myers Company Information Table 109. Bristol-Myers Business Overview Table 110. Bristol-Myers Cardiovascular Drug Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Bristol-Myers Cardiovascular Drug Therapy Product Portfolio Table 112. Bristol-Myers Recent Development Table 113. Amgen Company Information Table 114. Amgen Business Overview Table 115. Amgen Cardiovascular Drug Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Amgen Cardiovascular Drug Therapy Product Portfolio Table 117. Amgen Recent Development Table 118. AstraZeneca Company Information Table 119. AstraZeneca Business Overview Table 120. AstraZeneca Cardiovascular Drug Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. AstraZeneca Cardiovascular Drug Therapy Product Portfolio Table 122. AstraZeneca Recent Development Table 123. United Therapeutics Company Information Table 124. United Therapeutics Business Overview Table 125. United Therapeutics Cardiovascular Drug Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. United Therapeutics Cardiovascular Drug Therapy Product Portfolio Table 127. United Therapeutics Recent Development Table 128. Tasly Holding Group Company Information Table 129. Tasly Holding Group Business Overview Table 130. Tasly Holding Group Cardiovascular Drug Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. Tasly Holding Group Cardiovascular Drug Therapy Product Portfolio Table 132. Tasly Holding Group Recent Development Table 133. Lepu Medical Company Information Table 134. Lepu Medical Business Overview Table 135. Lepu Medical Cardiovascular Drug Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 136. Lepu Medical Cardiovascular Drug Therapy Product Portfolio Table 137. Lepu Medical Recent Development Table 138. CSPC Pharmaceutical Company Information Table 139. CSPC Pharmaceutical Business Overview Table 140. CSPC Pharmaceutical Cardiovascular Drug Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 141. CSPC Pharmaceutical Cardiovascular Drug Therapy Product Portfolio Table 142. CSPC Pharmaceutical Recent Development Table 143. CHIA TAI TIANQING Company Information Table 144. CHIA TAI TIANQING Business Overview Table 145. CHIA TAI TIANQING Cardiovascular Drug Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 146. CHIA TAI TIANQING Cardiovascular Drug Therapy Product Portfolio Table 147. CHIA TAI TIANQING Recent Development Table 148. Boehringer Ingelheim Company Information Table 149. Boehringer Ingelheim Business Overview Table 150. Boehringer Ingelheim Cardiovascular Drug Therapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 151. Boehringer Ingelheim Cardiovascular Drug Therapy Product Portfolio Table 152. Boehringer Ingelheim Recent Development Table 153. North America Cardiovascular Drug Therapy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. North America Cardiovascular Drug Therapy Market Size by Country (2021-2026) & (US$ Million) Table 155. North America Cardiovascular Drug Therapy Market Share by Country (2021-2026) Table 156. North America Cardiovascular Drug Therapy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. North America Cardiovascular Drug Therapy Market Share Forecast by Country (2027-2032) Table 158. Europe Cardiovascular Drug Therapy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Europe Cardiovascular Drug Therapy Market Size by Country (2021-2026) & (US$ Million) Table 160. Europe Cardiovascular Drug Therapy Market Share by Country (2021-2026) Table 161. Europe Cardiovascular Drug Therapy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Europe Cardiovascular Drug Therapy Market Share Forecast by Country (2027-2032) Table 163. Asia-Pacific Cardiovascular Drug Therapy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 164. Asia-Pacific Cardiovascular Drug Therapy Market Size by Country (2021-2026) & (US$ Million) Table 165. Asia-Pacific Cardiovascular Drug Therapy Market Share by Country (2021-2026) Table 166. Asia-Pacific Cardiovascular Drug Therapy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 167. Asia-Pacific Cardiovascular Drug Therapy Market Share Forecast by Country (2027-2032) Table 168. Latin America Cardiovascular Drug Therapy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 169. Latin America Cardiovascular Drug Therapy Market Size by Country (2021-2026) & (US$ Million) Table 170. Latin America Cardiovascular Drug Therapy Market Share by Country (2021-2026) Table 171. Latin America Cardiovascular Drug Therapy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 172. Latin America Cardiovascular Drug Therapy Market Share Forecast by Country (2027-2032) Table 173. Middle East & Africa Cardiovascular Drug Therapy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 174. Middle East & Africa Cardiovascular Drug Therapy Market Size by Country (2021-2026) & (US$ Million) Table 175. Middle East & Africa Cardiovascular Drug Therapy Market Share by Country (2021-2026) Table 176. Middle East & Africa Cardiovascular Drug Therapy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 177. Middle East & Africa Cardiovascular Drug Therapy Market Share Forecast by Country (2027-2032) Table 178. Research Programs/Design for This Report Table 179. Authors List of This Report Table 180. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Cardiovascular Drug Therapy Product Image Figure 3. Global Cardiovascular Drug Therapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Cardiovascular Drug Therapy Market Size (2021-2032) & (US$ Million) Figure 5. Global Cardiovascular Drug Therapy Market Share by Region: 2025 VS 2032 Figure 6. Global Cardiovascular Drug Therapy Market Share by Region (2021-2032) Figure 7. North America Cardiovascular Drug Therapy Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Cardiovascular Drug Therapy Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Cardiovascular Drug Therapy Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Cardiovascular Drug Therapy Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Cardiovascular Drug Therapy Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Oral Medication Image Figure 13. Global Oral Medication Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Injection Image Figure 15. Global Injection Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Global Cardiovascular Drug Therapy Market Size Overview by Type (2021-2032) & (US$ Million) Figure 17. Global Cardiovascular Drug Therapy Market Share by Type 2025 VS 2032 Figure 18. North America Cardiovascular Drug Therapy Market Size Share by Type (2021-2032) Figure 19. Europe Cardiovascular Drug Therapy Market Size Share by Type (2021-2032) Figure 20. Asia-Pacific Cardiovascular Drug Therapy Market Size Share by Type (2021-2032) Figure 21. Latin America Cardiovascular Drug Therapy Market Size Share by Type (2021-2032) Figure 22. Middle East and Africa Cardiovascular Drug Therapy Market Size Share by Type (2021-2032) Figure 23. Hospital Image Figure 24. Global Hospital Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Retail Image Figure 26. Global Retail Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Global Cardiovascular Drug Therapy Market Size Overview by Application (2021-2032) & (US$ Million) Figure 28. Global Cardiovascular Drug Therapy Market Share by Application 2025 VS 2032 Figure 29. North America Cardiovascular Drug Therapy Market Size Share by Application (2021-2032) Figure 30. Europe Cardiovascular Drug Therapy Market Size Share by Application (2021-2032) Figure 31. Asia-Pacific Cardiovascular Drug Therapy Market Size Share by Application (2021-2032) Figure 32. Latin America Cardiovascular Drug Therapy Market Size Share by Application (2021-2032) Figure 33. Middle East and Africa Cardiovascular Drug Therapy Market Size Share by Application (2021-2032) Figure 34. Global Top 5 and 10 Cardiovascular Drug Therapy Players Market Share by Revenue in 2025 Figure 35. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 36. North America Cardiovascular Drug Therapy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 37. North America Cardiovascular Drug Therapy Market Share by Country: 2021 VS 2025 VS 2032 Figure 38. North America Cardiovascular Drug Therapy Market Share by Country (2021-2032) Figure 39. Europe Cardiovascular Drug Therapy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 40. Europe Cardiovascular Drug Therapy Market Share by Country: 2021 VS 2025 VS 2032 Figure 41. Europe Cardiovascular Drug Therapy Market Share by Country (2021-2032) Figure 42. Asia-Pacific Cardiovascular Drug Therapy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 43. Asia-Pacific Cardiovascular Drug Therapy Market Share by Country: 2021 VS 2025 VS 2032 Figure 44. Asia-Pacific Cardiovascular Drug Therapy Market Share by Country (2021-2032) Figure 45. Latin America Cardiovascular Drug Therapy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Latin America Cardiovascular Drug Therapy Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Latin America Cardiovascular Drug Therapy Market Share by Country (2021-2032) Figure 48. Middle East & Africa Cardiovascular Drug Therapy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 49. Middle East & Africa Cardiovascular Drug Therapy Market Share by Country: 2021 VS 2025 VS 2032 Figure 50. Middle East & Africa Cardiovascular Drug Therapy Market Share by Country (2021-2032) Figure 51. Years Considered Figure 52. Research Process Figure 53. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Medication
  • Injection
Applications
  • Hospital
  • Retail
Companies covered
  • Zhejiang Huahai Pharmaceutical
  • Takeda
  • Sanofi
  • Johnson & Johnson
  • Qilu pharmaceutical
  • Novartis
  • Merck
  • Eli Lilly
  • Gilead
  • Pfizer
  • Daiichi Sankyo
  • Bayer
  • Bristol-Myers
  • Amgen
  • AstraZeneca
  • United Therapeutics
  • Tasly Holding Group
  • Lepu Medical
  • CSPC Pharmaceutical
  • CHIA TAI TIANQING
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Cardiovascular Drug Therapy Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Cardiovascular Drug Therapy Market Size by Region (2021-2032)
  5. 1.4.1 Global Cardiovascular Drug Therapy Market Size by Region (2021-2026)
  6. 1.4.2 Global Cardiovascular Drug Therapy Market Size by Region (2027-2032)
  7. 1.5 Key Regions Cardiovascular Drug Therapy Market Size (2021-2032)
  8. 1.5.1 North America Cardiovascular Drug Therapy Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Cardiovascular Drug Therapy Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Cardiovascular Drug Therapy Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Cardiovascular Drug Therapy Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Cardiovascular Drug Therapy Market Size Growth Rate (2021-2032)
2 Cardiovascular Drug Therapy Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Oral Medication
  3. 2.1.2 Injection
  4. 2.2 Global Cardiovascular Drug Therapy Market Size by Type
  5. 2.2.1 Global Cardiovascular Drug Therapy Market Size Overview by Type (2021-2032)
  6. 2.2.2 Global Cardiovascular Drug Therapy Historic Market Size Review by Type (2021-2026)
  7. 2.2.3 Global Cardiovascular Drug Therapy Market Size Forecasted by Type (2027-2032)
  8. 2.3 Global Cardiovascular Drug Therapy Market Size by Regions
  9. 2.3.1 North America Cardiovascular Drug Therapy Market Size Breakdown by Type (2021-2026)
  10. 2.3.2 Europe Cardiovascular Drug Therapy Market Size Breakdown by Type (2021-2026)
  11. 2.3.3 Asia-Pacific Cardiovascular Drug Therapy Market Size Breakdown by Type (2021-2026)
  12. 2.3.4 South America Cardiovascular Drug Therapy Market Size Breakdown by Type (2021-2026)
  13. 2.3.5 Middle East and Africa Cardiovascular Drug Therapy Market Size Breakdown by Type (2021-2026)
3 Cardiovascular Drug Therapy Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Hospital
  3. 3.1.2 Retail
  4. 3.2 Global Cardiovascular Drug Therapy Market Size by Application
  5. 3.2.1 Global Cardiovascular Drug Therapy Market Size Overview by Application (2021-2032)
  6. 3.2.2 Global Cardiovascular Drug Therapy Historic Market Size Review by Application (2021-2026)
  7. 3.2.3 Global Cardiovascular Drug Therapy Market Size Forecasted by Application (2027-2032)
  8. 3.3 Global Cardiovascular Drug Therapy Market Size by Regions
  9. 3.3.1 North America Cardiovascular Drug Therapy Market Size Breakdown by Application (2021-2026)
  10. 3.3.2 Europe Cardiovascular Drug Therapy Market Size Breakdown by Application (2021-2026)
  11. 3.3.3 Asia-Pacific Cardiovascular Drug Therapy Market Size Breakdown by Application (2021-2026)
  12. 3.3.4 South America Cardiovascular Drug Therapy Market Size Breakdown by Application (2021-2026)
  13. 3.3.5 Middle East and Africa Cardiovascular Drug Therapy Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Cardiovascular Drug Therapy Industry Trends
  2. 4.2 Cardiovascular Drug Therapy Industry Drivers
  3. 4.3 Cardiovascular Drug Therapy Industry Opportunities and Challenges
  4. 4.4 Cardiovascular Drug Therapy Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Cardiovascular Drug Therapy Revenue (2021-2026)
  2. 5.2 Global Cardiovascular Drug Therapy Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Cardiovascular Drug Therapy Key Company Headquarters & Area Served
  4. 5.4 Global Cardiovascular Drug Therapy Company, Product Type & Application
  5. 5.5 Global Cardiovascular Drug Therapy Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Cardiovascular Drug Therapy Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Cardiovascular Drug Therapy Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Cardiovascular Drug Therapy Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Zhejiang Huahai Pharmaceutical
  2. 6.1.1 Zhejiang Huahai Pharmaceutical Company Information
  3. 6.1.2 Zhejiang Huahai Pharmaceutical Business Overview
  4. 6.1.3 Zhejiang Huahai Pharmaceutical Cardiovascular Drug Therapy Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Zhejiang Huahai Pharmaceutical Cardiovascular Drug Therapy Product Portfolio
  6. 6.1.5 Zhejiang Huahai Pharmaceutical Recent Developments
  7. 6.2 Takeda
  8. 6.2.1 Takeda Company Information
  9. 6.2.2 Takeda Business Overview
  10. 6.2.3 Takeda Cardiovascular Drug Therapy Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Takeda Cardiovascular Drug Therapy Product Portfolio
  12. 6.2.5 Takeda Recent Developments
  13. 6.3 Sanofi
  14. 6.3.1 Sanofi Company Information
  15. 6.3.2 Sanofi Business Overview
  16. 6.3.3 Sanofi Cardiovascular Drug Therapy Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Sanofi Cardiovascular Drug Therapy Product Portfolio
  18. 6.3.5 Sanofi Recent Developments
  19. 6.4 Johnson & Johnson
  20. 6.4.1 Johnson & Johnson Company Information
  21. 6.4.2 Johnson & Johnson Business Overview
  22. 6.4.3 Johnson & Johnson Cardiovascular Drug Therapy Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Johnson & Johnson Cardiovascular Drug Therapy Product Portfolio
  24. 6.4.5 Johnson & Johnson Recent Developments
  25. 6.5 Qilu pharmaceutical
  26. 6.5.1 Qilu pharmaceutical Company Information
  27. 6.5.2 Qilu pharmaceutical Business Overview
  28. 6.5.3 Qilu pharmaceutical Cardiovascular Drug Therapy Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Qilu pharmaceutical Cardiovascular Drug Therapy Product Portfolio
  30. 6.5.5 Qilu pharmaceutical Recent Developments
  31. 6.6 Novartis
  32. 6.6.1 Novartis Company Information
  33. 6.6.2 Novartis Business Overview
  34. 6.6.3 Novartis Cardiovascular Drug Therapy Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Novartis Cardiovascular Drug Therapy Product Portfolio
  36. 6.6.5 Novartis Recent Developments
  37. 6.7 Merck
  38. 6.7.1 Merck Company Information
  39. 6.7.2 Merck Business Overview
  40. 6.7.3 Merck Cardiovascular Drug Therapy Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Merck Cardiovascular Drug Therapy Product Portfolio
  42. 6.7.5 Merck Recent Developments
  43. 6.8 Eli Lilly
  44. 6.8.1 Eli Lilly Company Information
  45. 6.8.2 Eli Lilly Business Overview
  46. 6.8.3 Eli Lilly Cardiovascular Drug Therapy Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Eli Lilly Cardiovascular Drug Therapy Product Portfolio
  48. 6.8.5 Eli Lilly Recent Developments
  49. 6.9 Gilead
  50. 6.9.1 Gilead Company Information
  51. 6.9.2 Gilead Business Overview
  52. 6.9.3 Gilead Cardiovascular Drug Therapy Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Gilead Cardiovascular Drug Therapy Product Portfolio
  54. 6.9.5 Gilead Recent Developments
  55. 6.10 Pfizer
  56. 6.10.1 Pfizer Company Information
  57. 6.10.2 Pfizer Business Overview
  58. 6.10.3 Pfizer Cardiovascular Drug Therapy Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Pfizer Cardiovascular Drug Therapy Product Portfolio
  60. 6.10.5 Pfizer Recent Developments
  61. 6.11 Daiichi Sankyo
  62. 6.11.1 Daiichi Sankyo Company Information
  63. 6.11.2 Daiichi Sankyo Business Overview
  64. 6.11.3 Daiichi Sankyo Cardiovascular Drug Therapy Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Daiichi Sankyo Cardiovascular Drug Therapy Product Portfolio
  66. 6.11.5 Daiichi Sankyo Recent Developments
  67. 6.12 Bayer
  68. 6.12.1 Bayer Company Information
  69. 6.12.2 Bayer Business Overview
  70. 6.12.3 Bayer Cardiovascular Drug Therapy Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Bayer Cardiovascular Drug Therapy Product Portfolio
  72. 6.12.5 Bayer Recent Developments
  73. 6.13 Bristol-Myers
  74. 6.13.1 Bristol-Myers Company Information
  75. 6.13.2 Bristol-Myers Business Overview
  76. 6.13.3 Bristol-Myers Cardiovascular Drug Therapy Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Bristol-Myers Cardiovascular Drug Therapy Product Portfolio
  78. 6.13.5 Bristol-Myers Recent Developments
  79. 6.14 Amgen
  80. 6.14.1 Amgen Company Information
  81. 6.14.2 Amgen Business Overview
  82. 6.14.3 Amgen Cardiovascular Drug Therapy Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Amgen Cardiovascular Drug Therapy Product Portfolio
  84. 6.14.5 Amgen Recent Developments
  85. 6.15 AstraZeneca
  86. 6.15.1 AstraZeneca Company Information
  87. 6.15.2 AstraZeneca Business Overview
  88. 6.15.3 AstraZeneca Cardiovascular Drug Therapy Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 AstraZeneca Cardiovascular Drug Therapy Product Portfolio
  90. 6.15.5 AstraZeneca Recent Developments
  91. 6.16 United Therapeutics
  92. 6.16.1 United Therapeutics Company Information
  93. 6.16.2 United Therapeutics Business Overview
  94. 6.16.3 United Therapeutics Cardiovascular Drug Therapy Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 United Therapeutics Cardiovascular Drug Therapy Product Portfolio
  96. 6.16.5 United Therapeutics Recent Developments
  97. 6.17 Tasly Holding Group
  98. 6.17.1 Tasly Holding Group Company Information
  99. 6.17.2 Tasly Holding Group Business Overview
  100. 6.17.3 Tasly Holding Group Cardiovascular Drug Therapy Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 Tasly Holding Group Cardiovascular Drug Therapy Product Portfolio
  102. 6.17.5 Tasly Holding Group Recent Developments
  103. 6.18 Lepu Medical
  104. 6.18.1 Lepu Medical Company Information
  105. 6.18.2 Lepu Medical Business Overview
  106. 6.18.3 Lepu Medical Cardiovascular Drug Therapy Revenue, Global Share and Gross Margin (2021-2026)
  107. 6.18.4 Lepu Medical Cardiovascular Drug Therapy Product Portfolio
  108. 6.18.5 Lepu Medical Recent Developments
  109. 6.19 CSPC Pharmaceutical
  110. 6.19.1 CSPC Pharmaceutical Company Information
  111. 6.19.2 CSPC Pharmaceutical Business Overview
  112. 6.19.3 CSPC Pharmaceutical Cardiovascular Drug Therapy Revenue, Global Share and Gross Margin (2021-2026)
  113. 6.19.4 CSPC Pharmaceutical Cardiovascular Drug Therapy Product Portfolio
  114. 6.19.5 CSPC Pharmaceutical Recent Developments
  115. 6.20 CHIA TAI TIANQING
  116. 6.20.1 CHIA TAI TIANQING Company Information
  117. 6.20.2 CHIA TAI TIANQING Business Overview
  118. 6.20.3 CHIA TAI TIANQING Cardiovascular Drug Therapy Revenue, Global Share and Gross Margin (2021-2026)
  119. 6.20.4 CHIA TAI TIANQING Cardiovascular Drug Therapy Product Portfolio
  120. 6.20.5 CHIA TAI TIANQING Recent Developments
  121. 6.21 Boehringer Ingelheim
  122. 6.21.1 Boehringer Ingelheim Company Information
  123. 6.21.2 Boehringer Ingelheim Business Overview
  124. 6.21.3 Boehringer Ingelheim Cardiovascular Drug Therapy Revenue, Global Share and Gross Margin (2021-2026)
  125. 6.21.4 Boehringer Ingelheim Cardiovascular Drug Therapy Product Portfolio
  126. 6.21.5 Boehringer Ingelheim Recent Developments
7 North America
  1. 7.1 North America Cardiovascular Drug Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Cardiovascular Drug Therapy Market Size by Country (2021-2026)
  3. 7.3 North America Cardiovascular Drug Therapy Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Cardiovascular Drug Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Cardiovascular Drug Therapy Market Size by Country (2021-2026)
  3. 8.3 Europe Cardiovascular Drug Therapy Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Cardiovascular Drug Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Cardiovascular Drug Therapy Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Cardiovascular Drug Therapy Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Cardiovascular Drug Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Cardiovascular Drug Therapy Market Size by Country (2021-2026)
  3. 10.3 South America Cardiovascular Drug Therapy Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Cardiovascular Drug Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Cardiovascular Drug Therapy Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Cardiovascular Drug Therapy Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst